7th International CAA Conference

Welcome to the 7th International Cerebral Amyloid Angiopathy Conference. We have crafted a program that features cutting-edge research, translational ideas for clinical trials, and new knowledge on prevention and treatment of manifestations of CAA such as hemorrhagic stroke.

Eric Smith, MD, MPH
Steven Greenberg M.D. Ph.D.
Mark van Buchem MD, PhD
253
days
19
hours
54
min
45
sec

Message from the Chair

 

 

Welcome to the 7th International Cerebral Amyloid Angiopathy Conference. We have crafted a program that features cutting-edge research, translational ideas for clinical trials, and new knowledge on prevention and treatment of manifestations of CAA such as hemorrhagic stroke.

Because of the effects of the COVID pandemic, the Conference will now take place online over two days, 1-2 October 2020. Details and the revised program will be available soon. Abstracts submissions will be accepted for electronic or oral presentation.

Our field of CAA research is being transformed by an expanding array of CAA biomarkers, better radio-pathological correlation, new model systems, and increasing therapeutic options for trials. Attend the Conference to share your own work on CAA, learn about new research and techniques, and gather information on diagnosis and treatment to help your clinical practice. The Conference covers all aspects of CAA research including molecular, tissue- or animal-based, human subject research, and clinical trails. Attendees include basic scientists, clinicians, and clinical researchers.”

Warmest regards,

 

Eric Smith, MD, MPH

Professor of Neurology, University of Calgary

Chair, 7th International CAA Conference Organizing Committee

abstract submission

 

We postponed the Abstract Submission until mid-June! We will keep you informed as much as possible

 

We invite you to submit your best CAA-related research for presentation at the 7th CAA Conference.  This is the premiere meeting for the cerebral amyloid angiopathy field, bringing together leading laboratory scientists, patient-based investigators, clinicians, and representatives of the biopharmaceutical industry from around the world.

 

 

           

            Abstracts should be submitted through this email account: office@icaaconference.org

 

            Presentation Type

            We encourage both laboratory-based (preclinical) and patient-based (clinical) research abstracts.  When submitting abstracts, you should select the presentation type as clinical or preclinical.  

 

Abstracts accepted for the conference will be designated for presentation as oral platform talks or poster presentations.  

 

 

 

Submission Guidelines

–        All abstracts must be submitted via office@icaaconference.org  ONLY. Abstract sent by fax or e-mail will not be accepted.

–        All abstracts should be written in English.

–        It is the responsibility of the presenting author and the submitter to review the submission status & information and correct them. Submitters are responsible for any typo error in the abstract.

–        The presenting author’s name should be underlined.

–        The abstract should be limited to;

o   400 words (text only), or

o   300 words and up to 2 images or tables

–        An acknowledgement of the receipt of the abstract submission will be sent automatically to the submitter by e-mail upon the on-line submission.

 

 

Contact for Abstract

For any inquiries the regarding the abstract submissions, please contact the conference Secretariat.

 

office@icaaconference.org

 

We look forward joining us at the CAA online Conference.

 

On behalf of the 2020 Organizing Committee,

 

Eric Smith


Scientific Program Committee

Contact

MESSAGE SENT!

Organizing Committee 2020

Sponsors